t**u
发帖数: 1572 | |
t***y
发帖数: 2276 | 2 ding
It looks like it will go down a little mon-wed, but will go up thur-fri.
Then the market will drop again after Friday. |
t**u
发帖数: 1572 | 3 nice prediction
【在 t***y 的大作中提到】
: ding
: It looks like it will go down a little mon-wed, but will go up thur-fri.
: Then the market will drop again after Friday.
|
y*****l
发帖数: 5997 | 4 10 Stocks That Should See Gains This Week
by: Brian Nichols August 15, 2011
ALU, AMRN, BZ, CVI, GM, GT, LULU, RES, SIRI, URBN
http://seekingalpha.com/article/287310-10-stocks-that-should-se
Amarin Corporation (AMRN) gained 20% over the last 3 days still leaving a
loss of nearly 7% in one month. This company has seen yearly gains in excess
of 430% as its lead drug AMR101 has investors very excited. The company
surpassed all levels of clinical trials including two pivotal phase three
programs. The stock trades on future and promise and not fundamentals, which
always makes me nervous. There is no reason to believe this drug will not
be granted approval, however the FDA has made questionable decisions in the
past. This stock offers a good opportunity for investors who are trading
short term, as it will most likely continue to rise as the excitement builds
over the next several months. |
y*****l
发帖数: 5997 | 5 Aug. 17, 2011
http://finance.yahoo.com/news/Amarin-Present-Wedbush-pz-2951260
Press Release Source: Amarin Corporation plc On Friday August 12, 2011, 2:42
pm EDT
MYSTIC, Conn. and DUBLIN, Ireland, Aug. 12, 2011 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN - News), a clinical-stage biopharmaceutical
company with a focus on cardiovascular disease, today announced that Joseph
Zakrzewski, Amarin's Executive Chairman and Chief Executive Officer, will
present at the Wedbush Securities 2011 Life Sciences Management Access
Conference to be held at Le Parker Meridien in New York City. The
presentation will take place at 12:40pm ET on Aug. 17, 2011. A live webcast
of the presentation will be available at the following URL:
http://wsw.com/webcast/wedbush17/amrn/ |
y*****l
发帖数: 5997 | 6 发信人: fazeOX (faze), 信区: Stock
标 题: Re: 谁研究过AMRN吗？
发信站: BBS 未名空间站 (Sat Aug 13 22:33:21 2011, 美东)
不是专家，一起交流一下。
AMRN六月份股价大跌，原因是CEO说今年公司不会被收购，fast money很失望。
最近股价跌的原因是受大盘和DNDN双重影响。DNDN的的销售远低于预期，DNDN的股价的
暴跌，对biotech startup打击很大。但是DNDN的失利的原因很特殊，药价太高，
reimbursement的问题，还有一些医生对它的治疗效果并不是完全认同。DNDN这个例子
不应该推广到其它药上，所以AMRN不应该受DNDN的拖累。
按照公司的guidance，AMRN九月底之前递交NDA。前几天的conference call 上，这次
NDA包括了Anchor和 Marine trial data。Anchor的data能包括就去，这是很大的利好
消息。Marine trial的病人数量是3.8Million，而Anchor的人群数量是36million。
还有一个好消息就是SPA on CV outcomes trial，REDUCE-IT包括了一部分有糖尿病的
病人。明年九月股价可能"shooting the moon"。
目前一个很重要的问题是专利问题，能不能尽量延长专利保护时间。有传言说，一旦专
利问题清楚了，大药厂就会在收购支票上签字了。 |
y*****l
发帖数: 5997 | 7 发信人: uknowiknow (newguyintown), 信区: Stock
标 题: Re: 谁研究过AMRN吗？
发信站: BBS 未名空间站 (Sun Aug 14 13:01:00 2011, 美东)
赞due deligence。
AMRN 的专利我研究过。他们有6个patent applications pending，其中有两个close
to issuing。其中一个运气好的话，任何时候都可能issue。但这取决于专利局
examiner的个人尺度。如果再有一轮rejection的话，起码还要拖两到三个月。立马
issue的可能性70%吧。如果patent 有issue，再加upcoming NDA，股价会冲25。再一轮
rejection的话，会有小挫。不过有NDA支撑不会大跌。
专利早晚会issue，只是多早的问题。不过shareholder现在都急吼吼盼着buyout，所以
timing是个问题。 |
p********e
发帖数: 1960 | 8 好像到处都有人看好AMRN...明天我也买点屯着
【在 t***y 的大作中提到】
: ding
: It looks like it will go down a little mon-wed, but will go up thur-fri.
: Then the market will drop again after Friday.
|
K********g
发帖数: 9389 | 9 药是好药，就是因为不是美国公司，一直让我犹豫
【在 p********e 的大作中提到】
: 好像到处都有人看好AMRN...明天我也买点屯着
|
p********e
发帖数: 1960 | 10 Prediction so far...so far...
I am underwater with AMRN...
【在 t***y 的大作中提到】
: ding
: It looks like it will go down a little mon-wed, but will go up thur-fri.
: Then the market will drop again after Friday.
|
|
|
p********e
发帖数: 1960 | 11 Cow! On the way back to 10??
【在 K********g 的大作中提到】
: 药是好药，就是因为不是美国公司，一直让我犹豫
|
y*****l
发帖数: 5997 | 12 Amarin Heart-Drug Patent Application Rejected By US Patent Office
7 minutes ago - DJNF
By Peter Loftus
Of DOW JONES NEWSWIRES
The U.S. Patent & Trademark Office rejected Amarin Corp.'s (AMRN)
application for a patent covering an experimental heart drug derived from
fish oil, causing the Dublin-based company's American depositary shares to
fall as much as 9.5% Wednesday.
The drug, code-named AMR101, would treat high levels of triglycerides, a
fatty substance in the blood linked to risk for heart problems. Some
observers have projected its annual sales exceeding $2 billion.
Amarin had applied for a U.S. patent covering a method of treating high
triglycerides with the active ingredient in AMR101. The PTO, however, issued
a final rejection of the application on Aug. 12, according to a docket item
on the PTO website.
A copy of the rejection letter wasn't immediately available, and an Amarin
spokesman couldn't be reached.
A Canaccord Genuity analyst said in a research note Wednesday that issuance
of a patent for AMR101 could be postponed to the second half of 2012,
following an appeal by the company.
The PTO had laid out several objections in a preliminary rejection of the
patent application in June. In that document, the PTO said the application's
claims weren't patentable because they amounted to "double-patenting" of
claims cited in another patent application.
The other patent application is pending and covers the composition of the
drug.
Amarin shares recently fell 3.9% to $12.50 after falling as low as $11.76
earlier in the session.
-Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.
com
(END) Dow Jones Newswires
08-17-11 1551ET
Copyright (c) 2011 Dow Jones & Company, Inc. |
p********e
发帖数: 1960 | 13 Thanks! I just saw this news as well...was wondering why it dropped much...
【在 y*****l 的大作中提到】
: Amarin Heart-Drug Patent Application Rejected By US Patent Office
: 7 minutes ago - DJNF
: By Peter Loftus
: Of DOW JONES NEWSWIRES
: The U.S. Patent & Trademark Office rejected Amarin Corp.'s (AMRN)
: application for a patent covering an experimental heart drug derived from
: fish oil, causing the Dublin-based company's American depositary shares to
: fall as much as 9.5% Wednesday.
: The drug, code-named AMR101, would treat high levels of triglycerides, a
: fatty substance in the blood linked to risk for heart problems. Some
|
X*****s
发帖数: 2767 | 14 说个马后炮，上次justincase推荐过该股，我买过很快又卖了，因为看走势不对劲。
后来从19掉到了14，网上消息说是公司不想卖掉自己，fast money很失望，所以股价掉
了。对这个解释我一直怀疑，就算掉，也不至于掉这么多，超过25%的掉？
再次在这里提醒大家，生拉很危险，因为这些风投资金和大庄有各种各样的炒作办
法，花样层出不穷，配合美股里的short,option这些杆杠，简直是刀山火海，可以媲美
华山一条道和野人山。这些所谓的评论家都是明的暗的pumper，千万不能全信。
顺便问一下，这里有哪位高人，大量长线的hold一个生拉，忍受无数的心理煎熬，
仿佛是把自己当耗子一般从pre-clinical实验到到phase 3的，最后翻了5倍10倍的？
【在 y*****l 的大作中提到】
: Amarin Heart-Drug Patent Application Rejected By US Patent Office
: 7 minutes ago - DJNF
: By Peter Loftus
: Of DOW JONES NEWSWIRES
: The U.S. Patent & Trademark Office rejected Amarin Corp.'s (AMRN)
: application for a patent covering an experimental heart drug derived from
: fish oil, causing the Dublin-based company's American depositary shares to
: fall as much as 9.5% Wednesday.
: The drug, code-named AMR101, would treat high levels of triglycerides, a
: fatty substance in the blood linked to risk for heart problems. Some
|
t**u
发帖数: 1572 | 15 在低价买, 绝不在高价进货
【在 X*****s 的大作中提到】
: 说个马后炮，上次justincase推荐过该股，我买过很快又卖了，因为看走势不对劲。
: 后来从19掉到了14，网上消息说是公司不想卖掉自己，fast money很失望，所以股价掉
: 了。对这个解释我一直怀疑，就算掉，也不至于掉这么多，超过25%的掉？
: 再次在这里提醒大家，生拉很危险，因为这些风投资金和大庄有各种各样的炒作办
: 法，花样层出不穷，配合美股里的short,option这些杆杠，简直是刀山火海，可以媲美
: 华山一条道和野人山。这些所谓的评论家都是明的暗的pumper，千万不能全信。
: 顺便问一下，这里有哪位高人，大量长线的hold一个生拉，忍受无数的心理煎熬，
: 仿佛是把自己当耗子一般从pre-clinical实验到到phase 3的，最后翻了5倍10倍的？
|
i*****1
发帖数: 670 | 16 Patent declined
Careful!!!
【在 t**u 的大作中提到】
: amrn怎么样?
|
c*****1
发帖数: 25 | |
c*****1
发帖数: 25 | 18 oops
http://www.gekkowire.com/?p=7328
【在 c*****1 的大作中提到】
: 这篇三月的文章不错
|
